Ananda Pharma PLC has announced plans to withdraw from the AQSE Growth Market and re-register as a private company, citing the high cost of being publicly listed, regulatory complexity and limited liquidity in its shares.
The company estimates the move will save around £500,000 per year, funds it intends to reinvest directly into its core research and development programmes. This includes accelerating the development of MRX1 and advancing upcoming clinical trials for endometriosis and chemotherapy-induced peripheral neuropathy, both expected to begin in Q1 2026.
Ananda said the decision reflects a strategic shift toward a more efficient operating model, allowing management to focus on scientific progress without the financial and administrative burden of remaining listed.
Shareholders will still be able to participate in future funding rounds, which will be offered on the same terms as those provided to the Executive Chairman, who has personally invested more than £10 million in the company to date.
A General Meeting on 12 December 2025 will seek shareholder approval for the move, with the proposed delisting scheduled to take effect on or around 22 December 2025.
The company said the transition to a private structure will better support its long-term ambition to bring cannabinoid-based therapies closer to commercialisation.
